Plasma androgen concentrations and risk of incident ovarian cancer.

Plasma androgen concentrations and risk of incident ovarian cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Plasma androgen concentrations and risk of incident ovarian cancer. Abstract Text:

Shelley S Tworoger,I-Min Lee,Julie E Buring,Susan E Hankinson,Shelley S Tworoger,I-Min Lee,Julie E Buring,Susan E Hankinson,

Androgens have been implicated in increasing ovarian cancer risk; however, results from prospective studies have been inconclusive. The authors examined whether plasma concentrations of testosterone, androstenedione, dehydroepiandrosterone, and dehydroepiandrosterone sulfate were associated with risk of epithelial ovarian cancer in a nested-case control study, using data from three prospective cohort studies: the Nurses' Health Study (NHS), Nurses' Health Study II (NHSII), and the Women's Health Study (WHS). The present analysis comprised 224 cases (161 from the NHS/NHSII and 63 from the WHS) and 603 controls (matched at a ratio of 1:3 for the NHS/NHSII and 1:2 for the WHS), with follow-up of up to 14 years. Women ranged in age from 34 years to 72 years (mean age = 56 years). The authors did not observe any associations between plasma androgen levels and risk of ovarian cancer. For example, comparing the top quartile with the bottom quartile, the relative risk was 0.74 (95% confidence interval: 0.44, 1.25; p-trend = 0.34) for testosterone and 0.76 (95% confidence interval: 0.45, 1.30; p-trend = 0.65) for androstenedione. There was a suggestion that dehydroepiandrosterone and dehydroepiandrosterone sulfate were inversely associated with ovarian cancer risk among postmenopausal women (for top quartile vs. bottom, relative risks were 0.65 and 0.70, respectively). Overall, these results do not support a positive association between circulating androgen levels and ovarian cancer risk.

Plasma androgen concentrations and risk of incident ovarian cancer. Publishing Authors By Initials

SS Tworoger,IM Lee,JE Buring,SE Hankinson,SS Tworoger,IM Lee,JE Buring,SE Hankinson,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Plasma androgen concentrations and risk of incident ovarian cancer. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: American journal of epidemiology

VOLUME: 167

Page Numbers: 211-8

Journal Abbreviation: Am. J. Epidemiol.

ISSN: 1476-6256

DAY: 3

MONTH: 11

YEAR: 2007

Plasma androgen concentrations and risk of incident ovarian cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7910653

Plasma androgen concentrations and risk of incident ovarian cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Plasma androgen concentrations and risk of incident ovarian cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Plasma androgen concentrations and risk of incident ovarian cancer.

AFFILIATION: Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. nhsst@channing.harvard.edu

Country: United States

AGENCY: United States NCI

GRANT: R01 CA67262

ACRONYM: CA

MEDLINETA: Am J Epidemiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Plasma androgen concentrations and risk of incident ovarian cancer Related Publications

• A novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of cytochrome P4502S1 by both dioxin and hypoxia.
• A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer.
• A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.
• A prospective study of postmenopausal hormone use and ovarian cancer risk.
• Aspirin, NSAID, and Acetaminophen Use and the Risk of Endometrial Cancer.
• Association of activity and chronic disease risk factors: utility and limitations of objectively measured physical activity data.
• Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk.
• Birthweight and body size throughout life in relation to sex hormones and prolactin concentrations in premenopausal women.
• Body shape throughout life and correlations with IGFs and GH.
• Breastfeeding and risk of ovarian cancer in two prospective cohorts.
• Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer.
• Circulating colony stimulating factor-1 and breast cancer risk.
• Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women.
• Circulating levels of sex steroids and prolactin in premenopausal women and risk of breast cancer.
• Dietary patterns, the Alternate Healthy Eating Index and plasma sex hormone concentrations in postmenopausal women.
• Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women.
• Identification of novel dioxin-responsive genes by representational difference analysis.
• Identifying target genes of the aryl hydrocarbon receptor nuclear translocator (Arnt) using DNA microarray analysis.
• Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts.
• Menopausal and reproductive factors and risk of age-related macular degeneration.
• Physical activity and inactivity in relation to sex hormone, prolactin, and insulin-like growth factor concentrations in premenopausal women - exercise and premenopausal hormones.
• Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer.
• Plasma adiponectin concentrations and risk of incident breast cancer.
• Plasma androgen concentrations and risk of incident ovarian cancer.
• Prolactin and breast cancer risk.
• Relationship of plasma adiponectin with sex hormone and insulin-like growth factor levels.
• Reproducibility of proteomic profiles over 3 years in postmenopausal women not taking postmenopausal hormones.
• The role of the aryl hydrocarbon receptor nuclear translocator protein in aryl hydrocarbon receptor action.
• Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis.
• Why does ARNT2 behave differently from ARNT?